NetworkNewsBreaks – CytoDyn Inc. (CYDY) Presiden
Post# of 148327
(Total Views: 332)
Posted On: 08/27/2018 5:39:03 PM
NetworkNewsBreaks – CytoDyn Inc. (CYDY) President and CEO Discusses Company Research in Interview on Uptick Newswire’s “Stock Day” Podcast
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that the company’s president and CEO Nader Pourhassan was interviewed on Uptick Newswire’s “Stock Day” Podcast. Among other highlights, Pourhassan discussed the company’s main product, a humanized monoclonal antibody, which has demonstrated positive results in HIV patients in a human clinical trial. The antibody has received fast-track designation with the FDA, with the potential of approval in early 2019. In addition, Pourhassan discussed a letter of intent and acquisition of a company with advanced cancer treatment and the company’s newly-hired board member, Michael Klump.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that the company’s president and CEO Nader Pourhassan was interviewed on Uptick Newswire’s “Stock Day” Podcast. Among other highlights, Pourhassan discussed the company’s main product, a humanized monoclonal antibody, which has demonstrated positive results in HIV patients in a human clinical trial. The antibody has received fast-track designation with the FDA, with the potential of approval in early 2019. In addition, Pourhassan discussed a letter of intent and acquisition of a company with advanced cancer treatment and the company’s newly-hired board member, Michael Klump.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼